Datasets:
id int64 | platform_type string | seller_id string | platform_name string | product_name string | product_category string | prescription_required_legally int64 | prescription_verified int64 | product_registered int64 | seller_licensed int64 | pharmacist_consultation int64 | verified_supply_chain int64 | cold_chain_maintained int64 | manufacturer_origin string | quality_test_result string | sf_classification string | API_content_adequate int64 | price_vs_reference float64 | payment_method string | consumer_age_group string | consumer_education string | consumer_complaint_filed int64 | adverse_event_reported int64 | website_takedown int64 | year int64 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | social_media | EPHARM_00090 | TikTok | COVID_treatment | pandemic | 0 | 0 | 1 | 0 | 0 | 0 | 0 | India | fail | falsified | 1 | 0.71 | cryptocurrency | 25_34 | secondary | 0 | 0 | 0 | 2,023 |
2 | social_media | EPHARM_00774 | marketplace_app | antibiotic | prescription | 1 | 1 | 1 | 0 | 0 | 0 | 1 | India | pass | compliant | 1 | 1.13 | credit_card | 25_34 | secondary | 0 | 0 | 0 | 2,021 |
3 | social_media | EPHARM_00686 | Facebook | antihypertensive | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | China | fail | substandard | 0 | 0.84 | mobile_money | 35_49 | tertiary | 0 | 0 | 0 | 2,023 |
4 | social_media | EPHARM_00476 | Facebook | erectile_dysfunction | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | Europe | pass | compliant | 1 | 0.86 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,022 |
5 | social_media | EPHARM_00821 | Instagram | antibiotic | prescription | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | fail | falsified | 1 | 0.8 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,022 |
6 | social_media | EPHARM_00059 | dedicated_website | antibiotic | prescription | 1 | 0 | 0 | 0 | 0 | 0 | 0 | USA | pass | compliant | 1 | 0.85 | bank_transfer | 25_34 | primary | 0 | 0 | 0 | 2,022 |
7 | social_media | EPHARM_00721 | dedicated_website | weight_loss | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | local_SSA | pass | compliant | 1 | 0.5 | bank_transfer | 18_24 | secondary | 0 | 0 | 0 | 2,021 |
8 | social_media | EPHARM_00306 | dedicated_website | weight_loss | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 1 | USA | fail | substandard | 0 | 1.1 | bank_transfer | 50_plus | tertiary | 0 | 0 | 0 | 2,023 |
9 | social_media | EPHARM_00849 | WhatsApp | skin_lightening | cosmetic | 0 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 1.05 | cash_on_delivery | 18_24 | tertiary | 0 | 0 | 0 | 2,023 |
10 | social_media | EPHARM_00439 | Telegram | skin_lightening | cosmetic | 0 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.79 | mobile_money | 25_34 | tertiary | 0 | 0 | 0 | 2,024 |
11 | social_media | EPHARM_00224 | dedicated_website | antibiotic | prescription | 1 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 1 | 0.66 | mobile_money | 25_34 | tertiary | 1 | 0 | 0 | 2,024 |
12 | social_media | EPHARM_00893 | dedicated_website | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Europe | fail | substandard | 0 | 0.63 | cash_on_delivery | 35_49 | primary | 1 | 0 | 0 | 2,022 |
13 | social_media | EPHARM_00133 | dedicated_website | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 1 | 0 | 0 | India | fail | falsified | 1 | 1.08 | credit_card | 35_49 | secondary | 0 | 1 | 0 | 2,024 |
14 | social_media | EPHARM_00489 | marketplace_app | weight_loss | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | China | fail | substandard | 1 | 0.41 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,023 |
15 | social_media | EPHARM_00358 | marketplace_app | antibiotic | prescription | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.79 | cash_on_delivery | 25_34 | secondary | 0 | 0 | 0 | 2,020 |
16 | social_media | EPHARM_00147 | Facebook | weight_loss | lifestyle | 0 | 0 | 0 | 0 | 0 | 1 | 0 | Europe | fail | substandard | 0 | 0.8 | mobile_money | 35_49 | tertiary | 0 | 0 | 0 | 2,023 |
17 | social_media | EPHARM_00616 | Facebook | antimalarial | essential | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.77 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,024 |
18 | social_media | EPHARM_00779 | Instagram | supplement_vitamin | OTC | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | pass | compliant | 1 | 0.64 | cash_on_delivery | 25_34 | tertiary | 0 | 0 | 0 | 2,024 |
19 | social_media | EPHARM_00919 | dedicated_website | erectile_dysfunction | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 1 | 0.5 | mobile_money | 25_34 | primary | 0 | 0 | 0 | 2,023 |
20 | social_media | EPHARM_00132 | TikTok | antimalarial | essential | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | fail | substandard | 0 | 0.59 | cash_on_delivery | 25_34 | tertiary | 0 | 0 | 0 | 2,022 |
21 | social_media | EPHARM_00313 | Facebook | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 1 | 0.87 | credit_card | 18_24 | tertiary | 0 | 0 | 0 | 2,024 |
22 | social_media | EPHARM_00158 | WhatsApp | benzodiazepine | controlled | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 1 | 0.61 | cryptocurrency | 18_24 | tertiary | 0 | 0 | 0 | 2,024 |
23 | social_media | EPHARM_00863 | Facebook | erectile_dysfunction | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 1 | India | fail | substandard | 1 | 0.4 | cryptocurrency | 18_24 | tertiary | 0 | 0 | 0 | 2,024 |
24 | social_media | EPHARM_00029 | WhatsApp | weight_loss | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.86 | credit_card | 35_49 | primary | 0 | 1 | 0 | 2,024 |
25 | social_media | EPHARM_00412 | WhatsApp | weight_loss | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.63 | cash_on_delivery | 35_49 | tertiary | 0 | 0 | 0 | 2,023 |
26 | social_media | EPHARM_00173 | Telegram | benzodiazepine | controlled | 1 | 0 | 0 | 0 | 0 | 0 | 0 | local_SSA | fail | falsified | 0 | 0.29 | mobile_money | 18_24 | secondary | 0 | 0 | 0 | 2,023 |
27 | social_media | EPHARM_00590 | dedicated_website | antihypertensive | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | Europe | pass | compliant | 1 | 0.72 | credit_card | 25_34 | secondary | 0 | 0 | 0 | 2,024 |
28 | social_media | EPHARM_00702 | dedicated_website | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | substandard | 0 | 0.3 | credit_card | 25_34 | secondary | 0 | 0 | 0 | 2,024 |
29 | social_media | EPHARM_00077 | marketplace_app | antibiotic | prescription | 1 | 0 | 1 | 0 | 0 | 1 | 0 | Europe | fail | falsified | 1 | 1.03 | cash_on_delivery | 35_49 | tertiary | 1 | 0 | 0 | 2,021 |
30 | social_media | EPHARM_00995 | marketplace_app | opioid_analgesic | controlled | 1 | 0 | 0 | 0 | 0 | 1 | 0 | India | fail | substandard | 0 | 0.54 | mobile_money | 35_49 | tertiary | 0 | 0 | 0 | 2,020 |
31 | social_media | EPHARM_00725 | dedicated_website | antibiotic | prescription | 1 | 0 | 0 | 0 | 0 | 0 | 0 | local_SSA | pass | compliant | 1 | 0.45 | bank_transfer | 25_34 | primary | 0 | 0 | 0 | 2,023 |
32 | social_media | EPHARM_00367 | Facebook | antibiotic | prescription | 1 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | substandard | 0 | 0.41 | cash_on_delivery | 25_34 | tertiary | 0 | 0 | 0 | 2,024 |
33 | social_media | EPHARM_00461 | Facebook | contraceptive | reproductive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.37 | mobile_money | 35_49 | secondary | 0 | 0 | 0 | 2,024 |
34 | social_media | EPHARM_00866 | Telegram | skin_lightening | cosmetic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.75 | cash_on_delivery | 35_49 | tertiary | 0 | 0 | 0 | 2,022 |
35 | social_media | EPHARM_00102 | marketplace_app | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 1 | 0 | 0 | unknown | fail | substandard | 0 | 1.21 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,021 |
36 | social_media | EPHARM_00622 | Instagram | antidiabetic | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | USA | pass | compliant | 1 | 0.35 | bank_transfer | 50_plus | secondary | 1 | 0 | 0 | 2,020 |
37 | social_media | EPHARM_00351 | WhatsApp | benzodiazepine | controlled | 1 | 0 | 0 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.36 | mobile_money | 50_plus | secondary | 0 | 0 | 0 | 2,023 |
38 | social_media | EPHARM_00202 | Instagram | weight_loss | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 0 | 0.95 | cash_on_delivery | 35_49 | tertiary | 0 | 0 | 0 | 2,021 |
39 | social_media | EPHARM_00427 | darknet_market | antimalarial | essential | 1 | 0 | 0 | 0 | 0 | 1 | 0 | India | fail | substandard | 0 | 0.65 | mobile_money | 25_34 | primary | 0 | 0 | 0 | 2,023 |
40 | social_media | EPHARM_00653 | Telegram | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 1 | 0 | 0 | China | fail | substandard | 1 | 0.68 | mobile_money | 18_24 | secondary | 0 | 0 | 0 | 2,024 |
41 | social_media | EPHARM_00483 | TikTok | antidiabetic | NCD | 1 | 0 | 0 | 0 | 0 | 1 | 0 | India | fail | substandard | 0 | 0.94 | cash_on_delivery | 35_49 | primary | 0 | 0 | 0 | 2,024 |
42 | social_media | EPHARM_00049 | marketplace_app | antibiotic | prescription | 1 | 0 | 0 | 0 | 0 | 0 | 0 | China | pass | compliant | 1 | 0.79 | mobile_money | 25_34 | secondary | 1 | 0 | 0 | 2,022 |
43 | social_media | EPHARM_00383 | Facebook | antidiabetic | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.78 | cash_on_delivery | 50_plus | primary | 1 | 0 | 0 | 2,023 |
44 | social_media | EPHARM_00020 | Facebook | traditional_herbal | unregulated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | local_SSA | fail | substandard | 1 | 0.68 | cash_on_delivery | 18_24 | tertiary | 0 | 0 | 0 | 2,023 |
45 | social_media | EPHARM_00751 | dedicated_website | antimalarial | essential | 1 | 0 | 1 | 0 | 0 | 1 | 0 | Europe | pass | compliant | 1 | 0.57 | credit_card | 25_34 | tertiary | 1 | 0 | 0 | 2,021 |
46 | social_media | EPHARM_00677 | Facebook | COVID_treatment | pandemic | 0 | 0 | 1 | 0 | 0 | 0 | 0 | China | pass | compliant | 1 | 0.94 | cash_on_delivery | 35_49 | tertiary | 1 | 0 | 0 | 2,024 |
47 | social_media | EPHARM_00861 | WhatsApp | weight_loss | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 0 | 0.87 | bank_transfer | 35_49 | tertiary | 0 | 0 | 0 | 2,023 |
48 | social_media | EPHARM_00798 | Facebook | weight_loss | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | pass | compliant | 1 | 0.56 | mobile_money | 18_24 | secondary | 0 | 0 | 0 | 2,020 |
49 | social_media | EPHARM_00009 | darknet_market | antihypertensive | NCD | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | pass | compliant | 1 | 0.48 | credit_card | 18_24 | primary | 0 | 0 | 0 | 2,021 |
50 | social_media | EPHARM_00482 | marketplace_app | ARV_HIV | essential | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 0 | 0.72 | cash_on_delivery | 18_24 | tertiary | 1 | 0 | 0 | 2,022 |
51 | social_media | EPHARM_00178 | Facebook | opioid_analgesic | controlled | 1 | 0 | 0 | 0 | 0 | 0 | 0 | Europe | fail | falsified | 0 | 0.53 | credit_card | 35_49 | secondary | 0 | 0 | 0 | 2,023 |
52 | social_media | EPHARM_00846 | Facebook | erectile_dysfunction | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.74 | mobile_money | 35_49 | secondary | 0 | 0 | 0 | 2,024 |
53 | social_media | EPHARM_00143 | marketplace_app | benzodiazepine | controlled | 1 | 0 | 1 | 0 | 0 | 0 | 0 | local_SSA | pass | compliant | 1 | 0.78 | mobile_money | 50_plus | secondary | 0 | 0 | 1 | 2,024 |
54 | social_media | EPHARM_00818 | Instagram | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 0 | 0.62 | cash_on_delivery | 25_34 | tertiary | 0 | 0 | 0 | 2,024 |
55 | social_media | EPHARM_00584 | TikTok | traditional_herbal | unregulated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 0 | 0.77 | cash_on_delivery | 25_34 | tertiary | 0 | 0 | 0 | 2,023 |
56 | social_media | EPHARM_00041 | TikTok | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 1 | China | fail | substandard | 1 | 0.49 | cash_on_delivery | 18_24 | secondary | 1 | 0 | 0 | 2,024 |
57 | social_media | EPHARM_00741 | dedicated_website | antidiabetic | NCD | 1 | 1 | 1 | 0 | 0 | 0 | 0 | China | pass | compliant | 1 | 0.8 | bank_transfer | 50_plus | tertiary | 0 | 0 | 0 | 2,024 |
58 | social_media | EPHARM_00203 | Instagram | antimalarial | essential | 1 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | pass | compliant | 1 | 0.45 | cash_on_delivery | 35_49 | secondary | 0 | 0 | 0 | 2,023 |
59 | social_media | EPHARM_00634 | Instagram | ARV_HIV | essential | 1 | 0 | 0 | 0 | 0 | 0 | 1 | China | pass | compliant | 1 | 0.99 | mobile_money | 35_49 | primary | 0 | 0 | 0 | 2,021 |
60 | social_media | EPHARM_00290 | Facebook | opioid_analgesic | controlled | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.62 | mobile_money | 35_49 | secondary | 0 | 0 | 0 | 2,023 |
61 | social_media | EPHARM_00295 | dedicated_website | cancer_medicine | specialty | 1 | 1 | 0 | 0 | 0 | 0 | 0 | China | fail | falsified | 1 | 0.48 | cash_on_delivery | 35_49 | tertiary | 0 | 0 | 0 | 2,024 |
62 | social_media | EPHARM_00686 | dedicated_website | traditional_herbal | unregulated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.65 | mobile_money | 35_49 | tertiary | 1 | 0 | 0 | 2,024 |
63 | social_media | EPHARM_00553 | marketplace_app | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 0 | 0.59 | cash_on_delivery | 18_24 | primary | 1 | 0 | 0 | 2,023 |
64 | social_media | EPHARM_00539 | darknet_market | erectile_dysfunction | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 1 | 0.65 | cash_on_delivery | 25_34 | tertiary | 0 | 0 | 0 | 2,020 |
65 | social_media | EPHARM_00931 | dedicated_website | antibiotic | prescription | 1 | 0 | 1 | 0 | 0 | 0 | 0 | Europe | fail | substandard | 1 | 0.83 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,023 |
66 | social_media | EPHARM_00601 | TikTok | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.78 | mobile_money | 50_plus | secondary | 0 | 0 | 0 | 2,022 |
67 | social_media | EPHARM_00929 | Facebook | traditional_herbal | unregulated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.69 | cryptocurrency | 25_34 | tertiary | 1 | 0 | 0 | 2,022 |
68 | social_media | EPHARM_00610 | darknet_market | antimalarial | essential | 1 | 0 | 0 | 0 | 0 | 0 | 0 | China | fail | substandard | 0 | 0.81 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,023 |
69 | social_media | EPHARM_00800 | darknet_market | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 0 | 0.69 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,024 |
70 | social_media | EPHARM_00633 | Instagram | skin_lightening | cosmetic | 0 | 0 | 1 | 0 | 0 | 1 | 0 | China | pass | compliant | 1 | 0.58 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,024 |
71 | social_media | EPHARM_00151 | dedicated_website | benzodiazepine | controlled | 1 | 0 | 1 | 0 | 0 | 0 | 0 | India | fail | substandard | 0 | 0.75 | credit_card | 50_plus | tertiary | 1 | 0 | 0 | 2,022 |
72 | social_media | EPHARM_00852 | Facebook | skin_lightening | cosmetic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | China | fail | falsified | 1 | 0.56 | mobile_money | 25_34 | tertiary | 1 | 0 | 0 | 2,024 |
73 | social_media | EPHARM_00580 | dedicated_website | opioid_analgesic | controlled | 1 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 1 | 0.75 | cryptocurrency | 50_plus | primary | 0 | 0 | 0 | 2,023 |
74 | social_media | EPHARM_00164 | TikTok | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 1 | 0 | China | pass | compliant | 1 | 0.65 | credit_card | 35_49 | primary | 1 | 0 | 0 | 2,021 |
75 | social_media | EPHARM_00722 | darknet_market | antimalarial | essential | 1 | 0 | 0 | 0 | 0 | 0 | 0 | India | pass | compliant | 1 | 0.97 | credit_card | 35_49 | tertiary | 0 | 0 | 0 | 2,024 |
76 | social_media | EPHARM_00535 | Facebook | skin_lightening | cosmetic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | China | fail | falsified | 0 | 0.72 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,020 |
77 | social_media | EPHARM_00315 | Facebook | cancer_medicine | specialty | 1 | 0 | 0 | 0 | 0 | 0 | 1 | India | fail | falsified | 0 | 0.75 | cash_on_delivery | 35_49 | secondary | 0 | 0 | 0 | 2,024 |
78 | social_media | EPHARM_00158 | Instagram | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Europe | fail | falsified | 1 | 0.52 | bank_transfer | 18_24 | tertiary | 1 | 0 | 0 | 2,021 |
79 | social_media | EPHARM_00589 | dedicated_website | antimalarial | essential | 1 | 0 | 1 | 0 | 0 | 0 | 0 | local_SSA | fail | substandard | 0 | 1.17 | bank_transfer | 50_plus | secondary | 1 | 0 | 0 | 2,024 |
80 | social_media | EPHARM_00498 | Telegram | antihypertensive | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | China | fail | substandard | 0 | 0.44 | bank_transfer | 18_24 | tertiary | 1 | 0 | 0 | 2,024 |
81 | social_media | EPHARM_00225 | Instagram | erectile_dysfunction | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 0 | 0.88 | bank_transfer | 18_24 | secondary | 0 | 0 | 0 | 2,024 |
82 | social_media | EPHARM_00894 | WhatsApp | benzodiazepine | controlled | 1 | 0 | 1 | 0 | 0 | 0 | 0 | China | fail | substandard | 0 | 0.28 | cash_on_delivery | 25_34 | secondary | 1 | 0 | 0 | 2,022 |
83 | social_media | EPHARM_00900 | marketplace_app | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | pass | compliant | 1 | 0.62 | bank_transfer | 18_24 | primary | 0 | 0 | 0 | 2,023 |
84 | social_media | EPHARM_00236 | dedicated_website | antimalarial | essential | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 0 | 0.68 | cash_on_delivery | 50_plus | secondary | 0 | 0 | 0 | 2,021 |
85 | social_media | EPHARM_00746 | darknet_market | opioid_analgesic | controlled | 1 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 1 | 0.51 | mobile_money | 50_plus | secondary | 0 | 0 | 0 | 2,024 |
86 | social_media | EPHARM_00058 | marketplace_app | opioid_analgesic | controlled | 1 | 0 | 0 | 1 | 0 | 0 | 1 | India | fail | substandard | 0 | 0.68 | cash_on_delivery | 25_34 | secondary | 1 | 0 | 0 | 2,024 |
87 | social_media | EPHARM_00526 | dedicated_website | cancer_medicine | specialty | 1 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.97 | mobile_money | 35_49 | tertiary | 0 | 0 | 0 | 2,022 |
88 | social_media | EPHARM_00642 | Facebook | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 0 | 0 | 1 | India | pass | compliant | 1 | 0.85 | mobile_money | 50_plus | tertiary | 0 | 0 | 0 | 2,020 |
89 | social_media | EPHARM_00858 | Instagram | ARV_HIV | essential | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 1 | 0.22 | mobile_money | 18_24 | secondary | 0 | 0 | 0 | 2,024 |
90 | social_media | EPHARM_00867 | darknet_market | weight_loss | lifestyle | 0 | 0 | 1 | 0 | 0 | 0 | 0 | USA | pass | compliant | 1 | 0.73 | credit_card | 25_34 | tertiary | 0 | 0 | 0 | 2,021 |
91 | social_media | EPHARM_00597 | marketplace_app | antibiotic | prescription | 1 | 0 | 0 | 0 | 0 | 0 | 0 | China | fail | substandard | 1 | 0.64 | mobile_money | 35_49 | tertiary | 0 | 0 | 0 | 2,024 |
92 | social_media | EPHARM_00412 | WhatsApp | opioid_analgesic | controlled | 1 | 1 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 1 | 1.17 | mobile_money | 18_24 | tertiary | 0 | 0 | 0 | 2,023 |
93 | social_media | EPHARM_00103 | TikTok | antihypertensive | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | USA | pass | compliant | 1 | 0.58 | mobile_money | 18_24 | secondary | 1 | 0 | 0 | 2,020 |
94 | social_media | EPHARM_00476 | darknet_market | erectile_dysfunction | lifestyle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 1 | 0.6 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,022 |
95 | social_media | EPHARM_00799 | Instagram | antidiabetic | NCD | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 0 | 0.83 | cash_on_delivery | 35_49 | tertiary | 1 | 0 | 0 | 2,024 |
96 | social_media | EPHARM_00842 | WhatsApp | opioid_analgesic | controlled | 1 | 0 | 0 | 0 | 0 | 0 | 0 | unknown | fail | substandard | 0 | 1.04 | cash_on_delivery | 50_plus | secondary | 0 | 0 | 0 | 2,020 |
97 | social_media | EPHARM_00410 | dedicated_website | supplement_vitamin | OTC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | India | fail | falsified | 0 | 0.64 | cash_on_delivery | 18_24 | tertiary | 1 | 0 | 0 | 2,023 |
98 | social_media | EPHARM_00516 | Instagram | antihypertensive | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | pass | compliant | 1 | 0.31 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,024 |
99 | social_media | EPHARM_00110 | dedicated_website | COVID_treatment | pandemic | 0 | 0 | 1 | 0 | 0 | 0 | 0 | China | pass | compliant | 1 | 0.52 | credit_card | 35_49 | secondary | 0 | 0 | 0 | 2,023 |
100 | social_media | EPHARM_00527 | dedicated_website | antihypertensive | NCD | 1 | 0 | 1 | 0 | 0 | 0 | 0 | unknown | fail | falsified | 1 | 0.48 | mobile_money | 25_34 | secondary | 0 | 0 | 0 | 2,020 |
End of preview. Expand in Data Studio
Online Pharmacy & E-Pharmacy Regulation Dataset
Abstract
30,000 simulated online medicine purchase observations (10,000 per scenario) across three e-pharmacy platform types. Variables include platform, product category, seller licensing, prescription verification, SF classification, price, payment method, and consumer demographics. Three scenarios: licensed e-pharmacy (6% SF), social media marketplace (65%), rogue website/darknet (89%).
This dataset is entirely simulated. It must not be used for regulatory or enforcement decisions.
Validation
Usage
from datasets import load_dataset
dataset = load_dataset("electricsheepafrica/online-pharmacy-regulation", "social_media_marketplace")
df = dataset["train"].to_pandas()
print(df.groupby('platform_name')['quality_test_result'].apply(lambda x: (x=='fail').mean()))
References
- WHO (2024). SF medicines sold online.
- NABP (2023). 95% of online pharmacies non-compliant.
- Interpol Operation Pangea. Illicit online pharmacy crackdowns.
- LegitScript. 30,000+ rogue pharmacy websites.
Citation
@dataset{esa_epharmacy_2025,
title = {Online Pharmacy and E-Pharmacy Regulation Dataset},
author = {{Electric Sheep Africa}},
year = {2025},
publisher = {Hugging Face},
url = {https://huggingface.co/datasets/electricsheepafrica/online-pharmacy-regulation}
}
License
- Downloads last month
- 35